Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotie, a drug development company, has confirmed that UCB will not exercise its option to license the drug, SYN118 in Parkinson's disease (PD).
Subscribe to our email newsletter
SYN118 is a potent and selective inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD), which is an enzyme in the primary pathway responsible for the breakdown of tyrosine, the precursor of the neurotransmitter dopamine.
According to Biotie, the Phase 2a study of SYN118 did not show significant improvement in measures of PD motor function when compared to placebo.
The UCB collaboration also includes Biotie’s adenosine A2a receptor antagonist tozadenant (SYN115), which is in phase 2b development for Parkinson’s disease, and the SYN118 decision has no impact on it.